Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SRK-439 · 1 trial · 1 indication
• Incidence of AEs
| Arm | Type | Description |
|---|---|---|
| Part A | EXPERIMENTAL | Participants will be treated with a single dose of SRK-439 or matching placebo. |
| Part B | EXPERIMENTAL | Participants will be treated with multiple doses of SRK-439 or matching placebo. |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Matching placebo to SRK-439, subcutaneous administration |
| SRK-439 | DRUG | Single ascending dose, subcutaneous administration |
Key Inclusion Criteria: 1. Male or female participants, ≥18 to ≤55 years of age, at the time of informed consent 2. BMI of ≥18 kg/m2 to ≤35 kg/m2 (inclusive) at screening Exclusion Criteria: 1. Previous treatment with SRK-439 or apitegromab, or with other anti-myostatin therapies, including ACTR ...
SRK-439 is an investigational small molecule being developed by Scholar Rock Holding Corporation. It is in Phase 1 clinical development and is designed to target myostatin. The specific therapeutic indication for SRK-439 has not been disclosed.
SRK-439 targets myostatin, a protein that regulates muscle growth. By binding to myostatin, SRK-439 is designed to inhibit its activity. This mechanism is being evaluated in a Phase 1 trial in healthy adult volunteers.
SRK-439 is being developed by Scholar Rock Holding Corporation, which trades on the Nasdaq under the ticker SRRK. The company is responsible for the clinical development of SRK-439.
SRK-439 is in Phase 1 clinical development. It is not approved by the FDA and remains an investigational drug. The ongoing Phase 1 trial is evaluating the drug in healthy adult volunteers.
SRK-439 is being studied in a Phase 1 trial, NCT07444294, titled A Single- and Multiple-Ascending Dose Study of SRK-439 in Healthy Adults. The trial is currently recruiting and plans to enroll 76 participants in the United States.